ADXN today
$4.54-$0.75 (-14.08%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourLeaning Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $3.80
Key levels
Resistance$5.41
Resistance$5.04
Support$3.74
Support$3.10
Latest news & SEC filings
DealNeurosterix, a spin-out of Addex Therapeutics, raises $105 million in Series B round
All ADXN news →About Addex Therapeutics
Addex Therapeutics is a drug developer based in Geneva, Switzerland, working on orally taken small molecules that modulate receptor activity. Its programs include dipraglurant for recovery after stroke and brain injury, ADX71149 for an undecided indication, and GABAB PAM compounds for addiction disorders and persistent cough. It partners with other drugmakers such as Indivior and Sinntaxis, and owns a stake in the spin-out Neurosterix.
Based on the company's 20-F filed May 15, 2026.
Nasdaq · Healthcare
Addex Therapeutics Ltd. (ADXN)
What Is the Price Target for ADXN?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is ADXN a Buy or Sell Right Now?
Thesis
- •Revenue growing -74.5% YoY with DECLINING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ADXN.
Start Free Trial →Is ADXN Overvalued or Undervalued?
Valuation Verdict
N/A
Methods Used
N/A
Fair Value
$N/A
29
Moat Score
NONE
3/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with ADXN?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Nunn Jason Raleigh | director | Sale | 219,561 | - | Sep 2, 2026 |
| Nunn Jason Raleigh | director | Buy | 219,561 | - | Sep 2, 2026 |
| Mills Roger | director officer | Sale | 392,837 | - | Sep 2, 2026 |
| Mills Roger | director officer | Buy | 392,837 | - | Sep 2, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ADXN Growth Story
Revenue YoY
-74.5%
3yr Revenue CAGR
-47.6%
EPS Growth YoY
151.03%
FCF Growth YoY
31.5%
Revenue Trend
DECLINING
Dark Pool Trades for ADXN
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ADXN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:43:20 | $4.51 | 2,650 | $$12K | BUY |
| 17:32:12 | $4.47 | 1,213 | $$5K | SELL |
| 17:25:13 | $4.57 | 1,024 | $$5K | BUY |
| 17:23:18 | $4.54 | 1,000 | $$5K | BUY |
| 17:22:27 | $4.44 | 1,000 | $$4K | SELL |
5 dark pool trades shown · $$31K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Addex Therapeutics Ltd. (ADXN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ADXN — frequently asked questions
What is ADXN stock price today?
Addex Therapeutics Ltd. (ADXN) is at $4.54, down 14.08% (-$0.75) at the Nov 13, 2026 close.
Why is ADXN stock moving today?
Latest ADXN news — Nov 13, 2026: Neurosterix, a spin-out of Addex Therapeutics, raises $105 million in Series B round
Did ADXN beat earnings?
ADXN last reported on Sep 28, 2026: EPS -$1.49.
Does ADXN pay a dividend?
ADXN does not currently pay a dividend.
What are ADXN support and resistance levels?
Support: $3.74, $3.10, $2.56. Resistance: $5.04, $5.41, $5.99.
What are insiders doing with ADXN?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on ADXN?
Nov 13, 2026: Neurosterix, a spin-out of Addex Therapeutics, raises $105 million in Series B round